Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
The prevalence of anemia in the patients who survived and died due to myocardial infarction (MI).
3
Zitationen
3
Autoren
2015
Jahr
Abstract
<b>Introduction & Objective:</b> Ischemia heart disease (IHD) is the most often met reason for losses in different communities. The most common reason of IHD is Atherosclerosis, and various etiologic factors such as high blood pressure, diabetes, smoking, and hyperlipidemia are involved in its development. Anemia is also considered another resulting reason of loss and morbidity in patients via IHD. Accordingly, the current paper aimed to determine the prevalence of anemia in patients who survived and died of myocardial infarction. <b>Materials and Methods:</b> The present research is of a case-control type, and the subjects were the patients with myocardial infarction admitted to Heart Ward of Hamadan Ekbatan Hospital within one year (2012-2013). The patients were divided into two categories of demised and survived after myocardial infarction, and in each 160-subject group, the prevalence of anemia with hemoglobin levels was investigated. Moreover, the demographic characteristics, ejection fraction, and patients' underlying medical conditions were also taken into account. The data obtained were analyzed by SPSS 15 software and chi-square test. <b>Results:</b> Of the 320 patients studied, 61 patients (19.1%) had anemia and 51 (83.6%) patients who were anemic had died. 31.7% of the deceased patients after MI were weak, while 6.3% of the survived patients after MI were anemic. Also, in all age and sex groups, anemia in the former patient group was higher than in the sustained group. The predominance of anemia was clearly greater in the women than in the men (P < 0.05). <b>Conclusion:</b> Based on the findings, there is a statistically clear variation in the prevalence of anemia in the former patient group after MI than in the group who survived after MI.
Ähnliche Arbeiten
The Ferric Reducing Ability of Plasma (FRAP) as a Measure of “Antioxidant Power”: The FRAP Assay
1996 · 22.104 Zit.
Anemia of Chronic Disease
2005 · 3.705 Zit.
Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease
2006 · 2.734 Zit.
Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
2013 · 2.172 Zit.
Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia
2006 · 2.089 Zit.